Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa™ (andexanet alfa) at Neurocritical Care Society 2...
13 Septembre 2016 - 2:00PM
Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that
Phase 3 clinical data and preclinical data from studies of the
Company’s Factor Xa inhibitor antidote AndexXaTM (andexanet
alfa) will be presented in poster sessions at the upcoming 14th
Annual Neurocritical Care Society Meeting, which will take place
from September 15-18 in National Harbor, Md. Additionally, results
of a retrospective chart review on treatment patterns and outcomes
of patients receiving oral Factor Xa inhibitors who experienced
life-threatening intracranial hemorrhage (ICH) will be presented in
a poster session.
AndexXa, a U.S. Food and Drug Administration
(FDA)-designated Breakthrough Therapy, is in development for
patients treated with a direct (apixaban, rivaroxaban, or edoxaban)
or indirect (enoxaparin) Factor Xa inhibitor when reversal of
anticoagulation is needed due to life-threatening or uncontrolled
bleeding. Currently, there is no FDA-approved antidote to
reverse the anticoagulant activity of Factor X inhibitors. Portola
is committed to conducting and supporting research to understand
the real-world management, outcomes and resource utilization of
Factor Xa inhibitor-associated major bleeding in order to improve
morbidity and mortality in these patients.
The abstracts are now available at
http://www.neurocriticalcare.org/Meetings/2016-Annual-Meeting/2016-Abstract-Submission-and-Poster-Information.
Following are details of the poster presentations, which will take
place in Prince George Exhibit Hall A of the Gaylord National
Resort and Convention Center. The posters will include additional
data not available in the posted abstracts.
AndexXa Poster Presentations
- Abstract Title: The effect of andexanet alfa
on the pharmacokinetics and renal clearance of the direct Factor Xa
inhibitorsAbstract Poster Number:
128Presenting Author: Janet M. Leeds, Ph.D.,
senior director, Drug Metabolism and Pharmacokinetics, Portola
PharmaceuticalsPresentation Date and Time: Friday,
September 16, 5:30-6:30 p.m. EDT
- Abstract Title: Andexanet alfa but not
prothrombin complex concentrate reverses rivaroxaban-induced
anticoagulation and reduces blood loss in a rabbit liver laceration
modelAbstract Poster Number: 8Presenting
Author: Polly Pine, Ph.D., head of pharmacology, Portola
Pharmaceuticals Presentation Date and Time:
Friday, September 16, 5:30-6:30 p.m. EDT
- Abstract Title: Andexanet alfa, an
investigational universal antidote for reversal of anticoagulation
of Factor Xa inhibitorsAbstract Poster Number:
135Presenting Author: Janet M. Leeds, Ph.D.,
senior director, Drug Metabolism and Pharmacokinetics, Portola
PharmaceuticalsPresentation Date and Time:
Saturday, September 17, 5:30-6:30 p.m. EDT
Retrospective Chart Review Poster
Presentation
- Abstract Title: Treatment patterns and
outcomes of patients receiving oral Factor Xa inhibitors or low
molecular weight heparin who experienced life-threatening
intracranial hemorrhage: A retrospective chart
reviewAbstract Poster Number: 78Presenting
Author: W. Richey Neuman, M.D., M.P.H., vice president,
Medical Affairs, Portola PharmaceuticalsPresentation Date
and Time: Friday, September 16, 5:30-6:30 p.m. EDT
About Portola Pharmaceuticals,
Inc.
Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company is advancing three programs, including betrixaban, an
oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur